Similar articles

• Selection of zidovudine-resistant variants of human immunodeficiency virus by therapy.

  Richman DD. Richman DD. Curr Top Microbiol Immunol. 1992;176:131-42. doi: 10.1007/978-3-642-77011-1_9. Curr Top Microbiol Immunol. 1992. PMID: 1600750 Review. No abstract available.
• Resistance of human immunodeficiency virus type 1 to antiretroviral agents: a review.

  Erice A, Balfour HH Jr. Erice A, et al. Clin Infect Dis. 1994 Feb;18(2):149-56. doi: 10.1093/clinids/18.2.149. Clin Infect Dis. 1994. PMID: 7512829 Review. No abstract available.
• Primary infection with zidovudine-resistant HIV.

  Hermans P, Sprecher S, Clumeck N. Hermans P, et al. N Engl J Med. 1993 Oct 7;329(15):1123; author reply 1124. doi: 10.1056/NEJM199310073291514. N Engl J Med. 1993. PMID: 8371738 No abstract available.
• Emergence of mutant HIV reverse transcriptase conferring resistance to AZT.

  Richman DD. Richman DD. J Enzyme Inhib. 1992;6(1):55-64. doi: 10.3109/14756369209041356. J Enzyme Inhib. 1992. PMID: 1285303 Review. No abstract available.
• Antiretroviral drug resistance mutations in antiretroviral-naive prisoners.

  Stone DR, Corcoran C, Wurcel A, McGovern B, Quirk J, Brewer A, Sutton L, D'Aquila RT. Stone DR, et al. Clin Infect Dis. 2002 Oct 1;35(7):883-6. doi: 10.1086/342697. Epub 2002 Sep 11. Clin Infect Dis. 2002. PMID: 12228827